The FDA granted breakthrough device designation to the Haystack MRD test, which uses ctDNA to detect residual or recurrent ...

Personalis' mission, since it was founded in 2011, is to transform the active management of cancer through breakthrough ...

CEO Chad Robins highlighted a strong year for Adaptive Biotechnologies, with MRD revenue increasing by 42% year-over-year. Key drivers included a higher gapfill rate of $2,007 for the clonoSEQ test ...

Myriad Genetics, Inc. MYGN recently announced that The Lancet Oncology has published a study demonstrating the performance of the company’s Precise MRD in patients with oligometastatic clear-cell ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca phase 3 clinical trial in lung cancer (NeoADAURA). The findings ...

Flatiron Health and Exact Sciences collaborate to use Flatiron's platform for rapid data analysis with the Oncodetect MRD test. The study involves 1350 patients in community settings, focusing on ...

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced The Lancet Oncology published a study highlighting the performance of Myriad’s ...

FOSTER CITY, Calif., April 28, 2025 /PRNewswire/ -- Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary ...

This week in oncology highlights breakthroughs in cancer diagnostics and therapies, offering new hope for patients with ...

(RTTNews) - Myriad Genetics, Inc. (MYGN) announced new interim data from the MONSTAR-SCREEN-3 study, showcasing the high sensitivity and pan-cancer applicability of its Precise Minimal Residual ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its whole-genome sequencing (WGS)-based platform for minimal residual disease (MRD) testing ...